Proteon logo     Print Page | Close Window

SEC Filings

S-1/A
PROTEON THERAPEUTICS INC filed this Form S-1/A on 10/07/2014
Entire Document
 

Table of Contents


SELECTED FINANCIAL DATA

        The selected statements of operations data for the years ended December 31, 2012 and 2013 and the balance sheet data at December 31, 2012 and 2013 have been derived from our audited financial statements included elsewhere in this prospectus. The selected statement of operations data for the six months ended June 30, 2013 and 2014 and the selected balance sheet data at June 30, 2014 were derived from our unaudited financial statements appearing elsewhere in this prospectus. These unaudited financial statements have been prepared on a basis consistent with our audited financial statements and, in our opinion, contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. Our historical results for any prior period are not necessarily indicative of results to be expected in any future period, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period.

        The information set forth below should be read in conjunction with the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of this prospectus and with our financial statements and notes thereto included elsewhere in this prospectus. The selected financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus.

 
  Proteon Therapeutics, Inc.  
 
  Years Ended
December 31,
  Six Months Ended
June 30,
 
 
  2012   2013   2013   2014  
 
   
   
  (unaudited)
 
 
  (in thousands except share and per share data)
 

Operating expenses:

                         

Research and development

  $ 5,907   $ 3,994   $ 2,003   $ 2,785  

General and administrative

    2,089     3,128     1,417     1,656  
                   

Total operating expenses

    7,996     7,122     3,420     4,441  
                   

Loss from operations

    (7,996 )   (7,122 )   (3,420 )   (4,441 )

Other income (expense):

                         

Investment income

    20     4     3     3  

Interest expense

        (861 )       (857 )

Other income (expense)

    6     67     5     (99 )
                   

Total other income (expense)

    26     (790 )   8     (953 )
                   

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )
                   
                   

Unrealized (loss) gain on available-for-sale investments

    (5 )   (1 )       (23 )
                   

Comprehensive loss

  $ (7,975 ) $ (7,913 ) $ (3,412 ) $ (5,417 )
                   
                   

Reconciliation of net loss to net loss attributable to common stockholders

                         

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )

Accretion of redeemable convertible preferred stock to redemption value

    (6,133 )   (6,119 )   (3,039 )   (3,409 )
                   

Net loss attributable to common stockholders

  $ (14,103 ) $ (14,031 ) $ (6,451 ) $ (8,803 )
                   
                   

Net loss per share attributable to common stockholders—basic and diluted(1)(2)

  $ (61.66 ) $ (59.66 ) $ (27.97 ) $ (36.64 )
                   
                   

Weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted

    230,607     235,184     230,607     240,254  
                   
                   

Pro forma net loss per share attributable to common stockholders—basic and diluted (unaudited)(1)(2)

        $ (1.54 )       $ (0.66 )
                       
                       

Pro forma weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted (unaudited)

          4,565,620           6,763,218  
                       
                       

64